TAIPEI, Oct. 13, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle Society (WMS) 2025 International Congress in Vienna. Dr. Tahseen Mozaffar, an investigator of the study, presented the study outcome, emphasizing the therapeutic potential of AJ201 for SBMA patients.

Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve quality of life for patients and their caregivers1 Dual Breakthrough Therapy Designation (BTD) in China and the U.S. underscores Lundbeck's mission to advance brain health and transform lives of patients with ra

CAPE TOWN, South Africa, Oct. 13, 2025 /PRNewswire/ -- Singclean Medical, in partnership with Kayan Al-Seha Medical (KSM) and Professor Osama Shawki, successfully made its debut at the FIGO World Congress of Gynecology and Obstetrics 2025, held from October 5–9 at the Cape Town International Convention Centre. Participation at FIGO, marks a key milestone in Singclean's global strategy and growing influence in women's healthcare. Professor Osama Shawki's Keynote Highlights Singclean ® Adhesi

YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development. Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets.

SHANGHAI, Oct. 11, 2025 /PRNewswire/ -- Smartee Denti-Technology today announced the global launch of the Smartee Sleep Aligners, a clear aligner device designed to help manage obstructive sleep apnoea hypopnoea syndrome (OSAHS) and primary snoring (PS). The new series includes two versions: Smartee SA, which focuses on the treatment of OSAHS and PS, and Smartee SA Plus. The latter can treat OSAHS while simultaneously addressing orthodontic issues. Together, they provide clinicians with an inv

beast01/Getty Images To drive true innovation in drug development, executives must not let excitement about the latest shiny object obscure ultimate outcomes. Over the past 30 years, the clinical trial ecosystem has undergone remarkable technological transformation, such as the transition away from manual data entry to electronic data capture . Yet many organizations have struggled to translate technological excitement into meaningful operational efficiency. The time it takes to get final resul

gopixa/Getty Images The market outlook is full of uncertainty and pitfalls. Experts weigh in on how to mitigate risks. The pharmaceutical and biotechnology industry finds itself trying to navigate a market with increasing pitfalls. With funding constraints tightening and regulatory landscapes shifting, companies must orbit an increasingly complex environment while maintaining quality standards for successful drug development. A recent industry discussion featuring Marina Galvani, vice president,

iStock, Golden Sikorka Therapies from industry leaders BioMarin and Ascendis Pharma supply a key hormone that promotes bone growth. In order to move the field forward, challengers are looking to address the underlying cause of the rare, genetic disease. In November 2021, the FDA approved BioMarin’s Voxzogo for children 5 years and older with achondroplasia, giving hope to more than 10,000 patients and their families across the U.S. Voxzogo marked the industry’s first-ever therapy for the ra

iStock, Yutthana Gaetgeaw Heading into the final quarter of a year that has seen dramatic upheaval at the FDA—from the exodus of numerous senior leaders to unclear policy changes and a safety saga that engulfed the gene therapy space—drug approvals appear roughly on par with recent years. A chaotic nine months at the FDA has witnessed the toppling of more than half the agency’s senior leadership, the axing of 3,500 more staff and a safety scandal that upended the gene therapy sector, whi

Rasi Bhadramani/Getty Images While the benefits of AI are clear, the amount data sets needed for effective AI integration is proving to be a challenge. This is particularly true for cell therapy companies as they are eagerly seeking ways to reduce development costs. Two experts at Charles River Laboratories provide insights by giving their takeaways from their own AI integrations. Within the life sciences industry, companies are constantly experimenting with how to incorporate AI tools into thei